The insulin analog insulin glargine has a pharmacodynamic profile described as peakless and of longer duration than human NPH insulin (1). This allows for convenient once-daily dosing for coverage of basal insulin needs. We recently had the opportunity to examine whether this is the case in the...
The time course of action of regular and NPH insulins injected sc was studied in 15 insulin-treated diabetics over a 24-h period during which they received a constant infusion of glucose. The blood glucose began to decline in 1.2 +/- 0.1 h (range, 0.5--2) and reached its nadir in ...
Dual (NPH & regular) 10–16 hours 50%Insulinisophane (NPH)/50% regular 0.5–1 hour 2–12 hours 10–16 hours 50% Lisproprotamine/50% lispro 30–60 minutes Dual (lisproprotamine& lispro) 10–16 hours 75% Lisproprotamine/25% lispro ...
用Quizlet學習並牢記包含Insulin regular (HumuLINR)、Insulin rapid (aspart)、Insulin NPH (HumuLIN N)等詞語及更多內容的單詞卡。
Different doses of DPRO (0.1, 0.15, 0.2 U/kg) or equipotent doses of NPH ( 0.2, 0.3, 0.4 U/kg) were injected subcutaneously into the abdominal wall. The maximal metabolic effect (GIRmax) of DPRO was greater than that of NPH-insulin (p < 0.05). With increasing doses, GIRmax ...
Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans NN304 is a long-acting insulin analogue that is acylated with a 14-C-fatty acid chain. Protraction of action of this novel insulin analogue is due not to s... KH Fuchs...
In clinical studies in people with Type 1 and Type 2 diabetes, insulin glargine has demonstrated improved pre-breakfast blood glucose control and a reduction in the frequency of hypoglycaemia, especially nocturnal hypoglycaemia, in comparison with neutral protamine hagedorn (NPH) insulin. In addition,...
A key histopathological hallmark of Alzheimer’s disease (AD) is the presence of neurofibrillary tangles of aggregated microtubule-associated protein tau in neurons. Anle138b is a small molecule which has previously shown efficacy in mice in reducing tau
In order to fully exploit its metabolic advantages, it appears vital that the dose of insulin glargine should be titrated to achieve aggressive pre-breakfast blood glucose targets beyond those achievable with NPH in the absence of nocturnal hypoglycaemia. Insulin glargine appears to be a promising ...
Patients with T2DM at highrisk for cardiovascular disease (CVD) who were either drug naive or treated with oral antihyperglycemic agents or selectedinsulin regimens (human NPH, long-acting analog, or premixed) alone or in combination with oral antihyperglycemics wereeligible for inclusion. Randomized ...